FutureChem Co.,Ltd (Futurechem) aktie

FutureChem Co.,Ltd engages in the research and development, production, and sale of chemicals, pharmaceuticals, and medical devices in South Korea and internationally. The company offers radioactive pharmaceuticals, including [18F]FDG for the treatment of general cancer diagnosis, PDvue for Parkinson's disease, Alzavue for Alzheimer's disease, and FLT for the lung cancer diagnosis. Its products in pipeline include [18F]FC303, [177Lu]FC705, and 225Ac for the treatment of prostate cancer; F-FMT for brain tumor diagnosis; FC-505 for the treatment of arteriosclerosis and myocardial infarction; FC-211 for Alzheimer's disease; FC-2 for the treatment of hypoxia; FC-3 for solid cancer; FC801 for bladder cancer; and FC901 for the treatment of pulmonary fibrosis. The company also provides automatic synthesis equipment, such as sCUBE-RXN (synthetic), sCUBE-P&F (tablet-formulation), and sCUBE-M (radioactive, metal). In addition, it offers molecular imaging device airway sleeve and disposable cartridges, as well as engages in medical device wholesale and healthcare business. FutureChem Co.,Ltd was founded in 1999 and is headquartered in Seoul, South Korea.